Asymmetry Capital Management
VC Fund
San Francisco, United States
Asymmetry Capital Management is a VC fund in San Francisco focused on Biotechnology and Gaming. Asymmetry Capital Management, L.P. is a San Francisco-based alternative asset management firm founded in 2012 by Scott Kay, a 20-year veteran of health care investing. We utilize a data-driven primary research process to identify and invest in out-of-consensus health care companies that we believe have both asymmetric return profiles and near-termvaluation catalysts. Our differentiated investment process and focus on fundamental shorts seek to produce a return stream for investors that is both unique and repeatable over the long term. Asymmetry seeks to deliver high risk-adjusted returns, low correlations to both broad market and healthcare indices, and lower volatility.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Asymmetry Capital Management invests in
Stages Asymmetry Capital Management invests in
Countries Asymmetry Capital Management invests in
Investment Focus
Industry
- Biotechnology 2 (50%)
- Gaming 1 (25%)
- Medical 1 (25%)
- Health Care 1 (25%)
- Cryptocurrency 1 (25%)
Stage
- Seed 1 (25%)
- Series C 1 (25%)
- Series D 1 (25%)
- Post-IPO Equity 1 (25%)
Country
- Denmark 1 (25%)
- Switzerland 1 (25%)
- United States 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Anichess
|
Anichess develops a decentralized chess game. | $1.5M / Seed / Jun 22, 2023 | |
MoonLake Immunotherapeutics
|
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company crating novel therapies, and unlocking the potential of Sonelokimab, the novel investigational Nanobody® for the treatment of inflammation, to revolutionize outcomes for patients. | $115M / Post-IPO Equity / Apr 05, 2022 | |
Dice Therapeutics
|
DICE Therapeutics is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal ofachieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Company’s DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICE’s lead therapeutic candidate, S011806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. | $80M / Series C / Jan 08, 2021 | |
Galecto
|
Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medicalneed. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform. | $64M / Series D / Sep 25, 2020 |
Co-Investors
Cormorant Asset Management
2 deals together
OrbiMed
2 deals together
Soleus Capital
2 deals together
708 Capital
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Asymmetry Capital Management invest in?
Asymmetry Capital Management invests primarily in Biotechnology, Gaming and Medical startups, most often at Seed and Series C stage. Most of the 4 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Asymmetry Capital Management last invest?
The most recent investment recorded for Asymmetry Capital Management closed in Jun 2023. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
